Minimally Invasive Versus Conventional Coronary Bypass Surgery for Multivessel Coronary Disease
Yichen Gong,Tong Ding,Xiaoxiao Wang,Zhongqi Cui,Hong Zhao,Song Wu,Yuanhao Fu,Hang Yang,Yunpeng Ling
DOI: https://doi.org/10.1016/j.atssr.2024.10.024
2024-01-01
Annals of Thoracic Surgery Short Reports
Abstract:BACKGROUND Despite sternum-sparing and without cardiopulmonary bypass, the actual value of minimally invasive coronary surgery (MICS) is still debatable. This study aimed to compare the completeness of revascularization and intermediate-term outcomes of MICS with conventional sternotomy coronary artery bypass grafting (CABG). METHODS Two groups of 244 patients each, receiving MICS-CABG and sternotomy-CABG between November 2015 and March 2019, were matched using propensity score matching. The completeness of revascularization and major adverse cardiovascular and cerebrovascular events (MACCE; a composite of death, myocardial infarction, stroke, or repeated target vessel revascularization) were compared between the groups. RESULTS In the MICS-CABG group, the percentages of bypassed vessels 2, 3, and ≥ 4 were 53.7%, 36.1%, and 10.2%, respectively. Completeness of revascularization (95.5% vs 96.3%; P = .65) was comparable between MICS-CABG and sternotomy-CABG group. Postprocedural angiography revealed an overall patency of 96.2% (578/601) for the MICS-CABG group. At 5-year, both rates of MACCE (19.9% vs 22.1%; hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.49-1.32; P = .39), death (10.6% vs 12.9%; HR, 0.87; 95% CI, 0.46-1.65; P = .67), myocardial infarction (5.6% vs 4.2%; HR, 0.82; 95% CI, 0.27-2.52; P = .73), stroke (6.7% vs 6.6%; HR, 1.11; 95% CI, 0.43-2.86; P = .83) or repeated target vessel revascularization (1.9% vs 1.8%; HR, 0.85; 95% CI, 0.17-3.15; P = .84) was similar between MICS-CABG and sternotomy-CABG. CONCLUSIONS Compared with sternotomy-CABG, MICS-CABG appeared to yield non-inferior completeness of revascularization and intermediate-term MACCE, which could be an alternative for patients with multivessel coronary diseases.